2026-10-25
Fortive clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,946 −5.25%
S&P 7,428 −3.39%
GOLD $4,132 +1.46%
BTC $75,633 −5.94%
VIX 23.84 +43.53%
latest tape · as of 18:03 UTC
The Screen · Industrials · Scientific & Technical Instruments
Fortive
FTV · a US exchange · USD · Market cap $19.4B · 10,000 employees
Fortive Corporation designs, develops, manufactures, and markets products, software, and services in the United States, China, and internationally.
Not yet scored68.34 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 18:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price68.34 USD at the 4 Nov 2026 close
- Our value readFair vs our fair value, as of 4 Nov 2026
- Our regime readMarkup, as of 4 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.01)
- Last reviewed4 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $49.60 to $82.66, base estimate $66.82 (screen dated 2026-11-04).
- Trend Markup
- Insiders insiders sold, $1,708,247, latest filing 2026-10-30
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.01, read 2026-11-05
- Ethical screen not yet scored
Price68.34 USD
Fair value66.82
Ethical score87.1/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation55.76+22.6% to today ✓Distribution gives way to Accumulation
2026-10-02Read Distribution55.76+22.6% to today Accumulation gives way to Distribution after a 7% slide in 5 weeks
2026-08-30Read Accumulation60.08+13.7% to today ✓Markup gives way to Accumulation after a 6% slide in 4 weeks
2026-07-30Read Markup64.09+6.6% to today ✓Markdown gives way to Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Fortive holds its Markup at $68.34. The statistical read favours the buyers, held for 47 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 47 days |
| Price at the screen | $68.34 |
| Valuation | 30.91 trailing · 19.73 forward price to earnings |
| Values screen | Not scored · score 87.1 |
| Beta | 0.99 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 28.17% | Below 33% | Interest-bearing debt is just 28.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 9.02% | Below 49% | Money owed to the company is 9.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Fortive clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Fortive clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: narrow competitive moat, 7.80% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 2.3% above the base estimate.
Third-party analyst targets: 14 covering, consensus Hold. The average target sits −1% from the screen price.
Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.
Price History & ProjectionsWhere our models see it going: fair-value estimate $66.82, with a range of $49.60 to $82.66, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsPrecision Tools Maker Sits Near Fair Value
Walk into any factory floor or hospital wing and the gauges, sensors and workflow software often trace back to Fortive. The firm splits its efforts between intelligent operating kit and advanced healthcare gear, posting 8 percent revenue growth and 13 percent profit margins.
Yet the shares trade at 61.78 dollars against our 64.21 dollar fair value, a margin of safety of just 4 percent that earns an overvalued call. Forward earnings sit at 19.2 times while return on equity is only 7 percent and the moat remains narrow, so the ethical pass does not outweigh the limited upside.
Analysts sit on hold with a 64 dollar median target. In this corner of industrials a modest multiple can mask peak-cycle earnings rather than signal a bargain, and the thin cushion leaves little room if growth slows. Analysis, not advice.
| Forward P/E | 19.7xexpensive even after accounting for its growth |
| Trailing P/E | 30.9xa premium valuation |
| EPS, trailing | 2.11 |
| EPS, forward | 3.31 |
| Revenue growth | +7.8%slow but positive growth |
| Profit margin | 14.8%thin but positive margins |
| Return on equity | 10.6%a modest return on shareholder capital |
| FCF yield | 5.06% |
| Dividend yield | 0.44% |
| Debt to equity | 0.60moderate, manageable leverage |
| Current ratio | 1.23adequate liquidity, worth monitoring |
| Beta | 0.99steadier than the market |
| Short interest, float | 0.08% |
| 52-week range | 49.03 - 67.03 |
| Moat | NARROW |
| Market cap | $19.4B |
| Employees | 10,000 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeFTV trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-04
Accumulation $66.81
+15.6% Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 15.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63.
2026-10-28
Accumulation $57.79
+0.0% Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27
Accumulation $57.79
+0.0% Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26
Accumulation $57.79
+0.0% Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Accumulation $57.79
+0.0% Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24
Accumulation $57.79
+0.0% Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23
Accumulation $57.79
+0.0% Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22
Accumulation $57.79
+0.0% Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Accumulation $57.79
+0.0% Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18
Accumulation $57.79
+3.6% Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (15 analysts) rates it hold, with a mean price target of $63.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Fortive (FTV) Backs Buybacks And Deals, Is The Valuation Already Full? Yahoo Finance · 5d ago
- The 5 most interesting analyst questions from Fortive’s Q3 earnings call Yahoo Finance · 5d ago
- Earnings Strength Could Be A Game Changer For Fortive Stock (FTV) Yahoo Finance · 6d ago
- Should Steris Stock Holders Look At Medtronic Instead? Yahoo Finance · 7d ago
- Fortive Corporation Q3 2026 Earnings Call Summary Yahoo Finance · 8d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
TRMBTrimble Inc.
MKSIMKS Inc
TDYTeledyne Technologies
CGNXCognex Corp
ESEESCO Technologies Inc.
COHRCoherent Corp.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-30 | Mulhall Christopher M. | VP - Chief Accounting Officer | S - Sale+OE | 26,055 | $1,708,247 |
| 2026-10-30 | Underwood Peter C | SVP - GC | S - Sale+OE | 48,442 | $3,129,353 |
| 2026-05-04 | UNDERWOOD PETER C | Officer | 47,557 | $2,891,941 | |
| 2026-05-04 | UNDERWOOD PETER C | Officer | 47,557 | $1,375,348 | |
| 2026-03-26 | LASSITER WRIGHT III | Director | 4 | $257 | |
| 2026-03-02 | DESJOURDY AMEE | Officer | 44,650 | · | |
| 2026-03-02 | MULHALL CHRISTOPHER M. | Officer | 15,111 | · | |
| 2026-03-02 | SOROYE OLUMIDE | Chief Executive Officer | 68,685 | · | |
| 2026-03-02 | UNDERWOOD PETER C | Officer | 17,175 | · | |
| 2026-03-02 | OKERSTROM MARK D | Chief Financial Officer | 41,210 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-07-20 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-07-20 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-07-20 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-07-07 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-07-07 | Ro Khanna | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $60.31 | -0.3% | · | $998 | -0.3% |
| 2 months | $58.36 | +3.1% | · | $1,031 | +3.1% |
| 3 months | $54.83 | +9.7% | $0.06 | $1,098 | +9.8% |
| 6 months | $55.40 | +8.6% | $0.06 | $1,087 | +8.7% |
| 1 year | $54.57 | +10.3% | $0.18 | $1,106 | +10.6% |
| 2 years | $54.70 | +10.0% | $0.42 | $1,107 | +10.7% |
| 3 years | $50.76 | +18.5% | $0.65 | $1,198 | +19.8% |
| 5 years | $52.76 | +14.0% | $1.08 | $1,161 | +16.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever FTV does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.